US Patent

US7846961 — α crystalline form of the arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it

Method of Use · Assigned to Les Laboratoires Servier SAS · Expires 2029-10-05 · 3y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a specific crystalline form of perindopril arginine, a process for its preparation, and pharmaceutical compositions containing it.

USPTO Abstract

α-crystalline form of the compound of formula (I): characterized by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful as inhibitors of angiotensin I converting enzyme.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3 Treatment of inflammatory conditions Caduet
U-3 Treatment of inflammatory conditions Caduet
U-3 Treatment of inflammatory conditions Caduet

Patent Metadata

Patent number
US7846961
Jurisdiction
US
Classification
Method of Use
Expires
2029-10-05
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Les Laboratoires Servier SAS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.